Anthony Fauci said the AstraZeneca vaccine was “very good” and the lack of up-to-date data in the United States was an “unforced error”.

Anthony Fauci, The leading US epidemiologist said on Tuesday that the COVID-19 vaccine from AstraZeneca / Oxford it probably is “very good”, despite the fact that the data presented by the pharmaceutical company in a press release this week they were not “entirely correct”.

“It is probably a very good vaccine”, said Fauci, the president’s medical adviser for the pandemic Joe biden and director of National Institute of Allergies and Infectious Diseases (NIAID), al programa “Good Morning America” ​​of ABC News.

“If you look at it the data is pretty good, but when they put it out in the press release it wasn’t quite right.” Explain.

Fauci’s comments come after a security and data watchdog expressed its AstraZeneca may have included outdated data in its clinical trials in the United States which has been shown to be 79% effective against covid-19 and 100% in severe cases of the disease.

Fauci said that junta, a group of independent medical experts from National Institutes of Health, who understands NIAID, has contacted the company to express their concerns about the way the company presented the data What “they were somewhat overwhelmed and could actually be a bit misleading. “

The American expert described the event as “unlucky», And assured that it was “An unforced error” This only increases public doubts about vaccines and could potentially raise more questions.

Regardless, Fauci, the U.S. Food and Drug Administration, said it will review the company’s data when it seeks approval for its vaccine in the United States, “Will review all data independently”, regardless of pharmacist evaluations.

Amid the uproar, AstraZeneca said on Tuesday in a new statement What to update its COVID-19 vaccine test data in the United States and present the new results in 48 hours.

“We looked at the preliminary assessment of the primary analysis and the results were consistent with the interim analysis. We are now completing the validation of the statistical analysis, ”the company noted. “We will immediately contact the an independent Data Safety Oversight Board (DSMB) to share our core analysis with the most recent efficacy data. We intend to publish the results of the primary analysis within 48 hours. “

KEEP READING: